NewAmsterdam Pharma Co N.V. (NASDAQ: NAMS)

NewAmsterdam Pharma Co N.V., with ticker symbol NAMS, is a late-stage biopharmaceutical company operating in the healthcare industry. The company is dedicated to improving patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well-tolerated.

NewAmsterdam Pharma's main business activities revolve around the development and commercialization of obicetrapib, a next-generation cholesterol ester transfer protein (CETP) inhibitor. This drug is being developed as a monotherapy and in combination with ezetimibe, an oral cholesterol absorption inhibitor. The company is also investigating obicetrapib as a fixed-dose combination with ezetimibe, aiming to submit a New Drug Application (NDA) for this combination therapy.

Obicetrapib has shown promise in clinical trials, demonstrating statistically significant reductions in low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (ApoB). The company believes that obicetrapib has the potential to be a once-daily oral CETP inhibitor for lowering LDL-C, if approved. Currently, NewAmsterdam Pharma is conducting two phase 3 pivotal clinical trials, BROADWAY and BROOKLYN, to evaluate obicetrapib as a monotherapy used as an adjunct to maximally tolerated lipid-lowering therapies to potentially enhance LDL-C lowering in patients with ASCVD and/or HeFH.

The company's competitive advantages lie in its proprietary technology and expertise in CETP inhibition, as well as its experienced management team. Notable members of this team include Dr. Michael Davidson, a leading expert in the field of lipidology, and Dr. John Kastelein, a renowned cardiologist and scientist. NewAmsterdam Pharma has also partnered with A. Menarini International Licensing S.A., part of Menarini Group, to commercialize obicetrapib in a single unit dose of 10 mg or less in the majority of European countries, if approved.

NewAmsterdam Pharma's customers are patients with high cholesterol and cardiovascular disease (CVD), as well as healthcare providers and payers. The company's primary products are obicetrapib and its fixed-dose combination with ezetimibe, designed to be used as adjuncts to diet and maximally tolerated lipid-lowering therapies to potentially enhance LDL-C lowering in patients with ASCVD and/or HeFH.

In addition to its clinical trials, NewAmsterdam Pharma is also exploring the potential of obicetrapib in other indications, including Alzheimer's disease and diabetes. The company believes that CETP inhibition may also play a role in mitigating the risk of developing these diseases, and is conducting preclinical studies to examine the potential of obicetrapib in these areas.

NewAmsterdam Pharma is led by a world-class team of industry veterans and is backed by leading life sciences investors, including Frazier Life Sciences, Bain Capital, Forbion, RA Capital, and Viking Global. The company's primary approach to lowering LDL-C involves CETP inhibition, a novel method that has been shown to effectively reduce cardiovascular risk. Obicetrapib, the company's leading CETP inhibitor, has been observed to lower LDL-C levels by approximately 51% in patients with moderately high LDL-C levels, with or without prior statin therapy. Furthermore, obicetrapib has been shown to reduce ApoB levels by approximately 63.4% in patients with HeFH and elevated levels of LDL-C.

The lipid-lowering therapy market is highly competitive, with established players such as statins, ezetimibe, Nexletol/Nexlizet, and PCSK9 inhibitors. However, NewAmsterdam Pharma believes that obicetrapib has the potential to differentiate itself from existing therapies through its novel mechanism of action and improved efficacy.